Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 6, 1996, Pages 2338-2343

  Biller, Beverly M K ^a   Molitch, Mark E ^c   Vance, Mary Lee ^b   Cannistraro, Kristin Baker ^a   Davis, Kenneth R ^a   Simons, Jarid A ^d   Schoenfelder, John R ^d   Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NORTHWESTERN UNIVERSITY MEDICAL CENTER   (United States)

^d Pharmacia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADULT; AGED; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOGONADISM; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PREMENOPAUSE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TUMOR REGRESSION;

EID: 0029885384     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.6.2338     Document Type: Article

References (21)

1. Liuzzi A, Dallabonzana D, Oppizzi G, et al. 1985 Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med. 313:656-659.
2. Molitch ME, Elton RL, Blackwell RE, et al. 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab. 60:698-705.
3. Thorner MO, Fluckinger E, Calne DB. 1980 Bromocriptine: A Clinical and Pharmacological Review. New York: Raven Press, pp 143-145.
4. Bevan JS, Webster J, Burke CW, Scanlon MF. 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 13:221-235.
5. Kleinberg DL, Boyd AE, Wardlaw S, et al. 1983 Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med. 309:704-709.
6. Vance ML, Lipper M, Klibanski A, Biller BMK, Samaan NA, Molitch ME. 1990 Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med. 112:668-673.
7. Ferrari C, Barbieri C, Caldara R, et al. 1986 Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab. 63:941-945.
8. Ferrari C, Crosignani PG. 1986 Medical treatment of hyperprolactinaemic disorders. Hum Reprod. 7:507-514.
9. Mattei AM, Ferrari C, Baroldi P, et al. 1988 Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab. 66:193-198.
10. Ciccarelli E, Giusti M, Miola C, et al. 1989 Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab. 69:725-728.
11. Ferrari C, Mattei A, Melis GB, et al. 1989 Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. J Clin Endocrinol Metab. 68:1201-1205.
12. Falsetti L, Zanagnolo V, Galbignani E. 1989 Cabergoline treatment of patients with microprolactinoma. Advances in Therapy. 6:303-309.
13. Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani PG. 1992 Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol (Copenh). 126:489-494.
14. Webster J, Piscitelli G, Polli A, et al. 1993 The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clin Endocrinol (Oxf). 39:323-329.
15. Webster J, Piscitelli G, Polli A, Ferrari C, Ismail I, Scanlon MF. 1994 A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 331:904-909.
16. Johnston DG, Hall K, Kendall-Taylor P, Patrick D, Watson M, Cook DB. 1984 Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Lancet. 2:187-192.
17. van't Verlaat JW, Croughs RJM. 1991 Withdrawal of bromocriptine after long-term therapy of macroprolactinomas; effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf). 34:175-178.
18. Esiri MM, Bevan JS, Burke CW, Adams CBT. 1986 Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and non-functioning macroadenomas of the pituitary gland. J Clin Endocrinol Metab. 63:383-388.
19. Melis GB, Gambacciani M, Paoletti AM, Mais V, Sghedoni D, Fioretti P. 1989 Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration. Fertil Steril. 52:412-415.
20. Webster J, Piscitelli G, Polli A, et al. 1992 Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol (Oxf). 37:534-541.
21. Page SR, Nussey SS. 1989 Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. J Obstet Gynecol. 10:156.